T. Rowe Price Associates’s Keros Therapeutics KROS Stock Holding History

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$507K	Buy	45,876 +16,177	+54%	+$250K	﹤0.01%	2453
2025 Q4	$605K	Sell	29,699 -20,282	-41%	-$356K	﹤0.01%	2309
2025 Q3	$791K	Buy	49,981 +1,566	+3%	+$23.1K	﹤0.01%	2164
2025 Q2	$647K	Buy	48,415 +5,188	+12%	+$70K	﹤0.01%	2187
2025 Q1	$441K	Sell	43,227 -866,480	-95%	-$10.1M	﹤0.01%	2299
2024 Q4	$14.4M	Sell	909,707 -604,798	-40%	-$31.4M	﹤0.01%	1060
2024 Q3	$87.9M	Buy	1,514,505 +326,595	+27%	+$16.1M	0.01%	595
2024 Q2	$54.3M	Sell	1,187,910 -30,594	-3%	-$1.64M	0.01%	698
2024 Q1	$80.7M	Buy	1,218,504 +176,803	+17%	+$10.5M	0.01%	595
2023 Q4	$41.4M	Sell	1,041,701 -225,531	-18%	-$7.07M	0.01%	761
2023 Q3	$40.4M	Sell	1,267,232 -3,129	-0.2%	-$117K	0.01%	747
2023 Q2	$51M	Buy	1,270,361 +117,845	+10%	+$5.17M	0.01%	701
2023 Q1	$49.2M	Buy	1,152,516 +531,327	+86%	+$26.8M	0.01%	689
2022 Q4	$29.8M	Buy	621,189 +611,459	+6,284%	+$28.6M	﹤0.01%	810
2022 Q3	$367K	Buy	+9,730	New	+$337K	﹤0.01%	2282
2022 Q2	–	Sell	-4,505	Closed	-$245K	–	2992
2022 Q1	$245K	Sell	4,505 -2,062	-31%	-$106K	﹤0.01%	2636
2021 Q4	$384K	Buy	+6,567	New	+$327K	﹤0.01%	2507